A restatement by Mylan of EpiPen profit figures is just the latest problem for the drugmaker. » Read More
If implemented, Clinton's plan would increase the number of Americans insured while Trump's would not. » Read More
Gen Y: Do you have a co-signer on that student loan? Are you launching a start-up? Here's why you may need life insurance.
In this week's Trader Poll, tell us how Aviva, AXA, Allianz and Legal & General will fare this year.
People with three or more chronic illnesses and functional limitations tend to be poorer and older.
Mylan is trying to win over critics by issuing coupons to help consumers pay for its high-priced EpiPen. Don't be fooled, says Vox writer Sarah Kliff.
Wall Street likes health care despite its vulnerability to political headwinds and underperformance this year.
The savings came under a program where health providers coordinate care for 7.7 million Medicare beneficiaries.
Obamacare rates are 7 percent less in states with greater Medicaid eligibility, a new analysis says.
Most HealthCare.gov customers could buy health plans for under $100 per month next year even if prices grew by 25 percent.
Should you buy long-term-care insurance? That's the question for workers nearing retirement. The cost of coverage and care is rising.
Mylan raised the prices of 24 drug products more than 20 percent. One went up by 542 percent. Another by 444 percent.
Mylan has increased the price of the anti-allergy device EpiPen more than five-fold in recent years.
Insurance premiums on terrorism-coverage are unlikely to rise in the near-term due to regulations in the U.S., says QuoteWright's John Cook.
A troubling call came in to Morgan Stanley's internal hotline in May 2010, the New York Times reports.
As much as 55 percent of the country will have two or fewer Obamacare insurers to choose from.
Health savings accounts let you save for health-care expenses and retirement if you use them effectively. Are you spending or saving?
The inquiry relates to people who are eligible for Medicare and Medicaid.
Get the best of CNBC in your inbox